MoonLake Immunotherapeutics/$MLTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Ticker
$MLTX
Sector
Primary listing
Employees
100
Headquarters
Zug, Switzerland
Website
MLTX Metrics
BasicAdvanced
$3.4B
-
-$2.79
1.27
-
Price and volume
Market cap
$3.4B
Beta
1.27
52-week high
$61.87
52-week low
$31.42
Average daily volume
545K
Financial strength
Current ratio
16.647
Quick ratio
15.661
Long term debt to equity
20.734
Total debt to equity
21.167
Interest coverage (TTM)
-97.70%
Profitability
EBITDA (TTM)
-199.04
Effective tax rate (TTM)
-0.21%
Management effectiveness
Return on assets (TTM)
-24.99%
Return on equity (TTM)
-40.34%
Valuation
Price to book
9.56
Price to tangible book (TTM)
9.56
Price to free cash flow (TTM)
-20.163
Free cash flow yield (TTM)
-4.96%
Free cash flow per share (TTM)
-2.642
Growth
Earnings per share change (TTM)
204.52%
3-year earnings per share growth (CAGR)
-19.47%
Bulls say / Bears say
The Phase 3 VELA program for sonelokimab remains on schedule for a primary endpoint readout around September 2025, providing a near-term catalyst and reducing risk for the asset ahead of a planned mid-2026 BLA submission (MoonLake Q2 2025 Release)
MoonLake closed Q2 2025 with $425.1 million in cash and can access up to an additional $425 million through a non-dilutive debt facility, ensuring funds to advance its clinical programs through key milestones and into commercialization (MoonLake Q2 2025 Release)
Pharmaceutical giant Merck reportedly held talks to acquire MoonLake for more than $3 billion, underscoring the strategic value that investors see in sonelokimab’s potential (Financial Times)
Research and development expenses climbed to $49.8 million in Q2 2025, up from $36.5 million in the prior quarter, accelerating cash burn and potentially reducing the company's cash runway unless additional financing is secured (MoonLake Q2 2025 Release)
The imminent September 2025 readout of the Phase 3 VELA trials is a binary event; failure to meet the primary endpoint could significantly harm MoonLake’s valuation (MoonLake Q2 2025 Release)
UCB’s BIMZELX delivered sustained two-year disease control in hidradenitis suppurativa with over 83% of patients remaining flare-free, raising the competitive bar for sonelokimab to distinguish itself in the market (UCB EHSF 2025 Release)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MoonLake Immunotherapeutics stock?
MoonLake Immunotherapeutics (MLTX) has a market cap of $3.4B as of September 16, 2025.
What is the P/E ratio for MoonLake Immunotherapeutics stock?
The price to earnings (P/E) ratio for MoonLake Immunotherapeutics (MLTX) stock is 0 as of September 16, 2025.
Does MoonLake Immunotherapeutics stock pay dividends?
No, MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next MoonLake Immunotherapeutics dividend payment date?
MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.